Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) ± topotecan in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A
Dar, S
Borok, R
Lisak, L
Andrews, C
Ekbal, M
Mazzoran, L
Zorat, F
Rifkin, S
Robin, E
Gregory, S
Venugopal, P
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Rush Canc Inst, Chicago, IL 60612 USA
[2] NW Community Hosp, Arlington Hts, IL USA
[3] Ingalls Mem Hosp, Harvey, IL USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1365
引用
收藏
页码：305A / 305A
页数：1
相关论文
共 50 条
  • [1] Cytopenias improve in response to amifostine pentoxifylline/ciprofloxacin/dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Qawi, H
    Naseer, OB
    Dar, S
    Lisak, L
    Andric, T
    Ali, SI
    Quadri, M
    Ahmed, B
    Venugopal, P
    Gezer, S
    Gregory, S
    Loew, J
    Robin, E
    Rifkin, S
    BLOOD, 1998, 92 (10) : 631A - 631A
  • [2] Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Dutt, D
    Dean, L
    Fantroy, L
    Syed, E
    Gezer, S
    Hsu, WT
    Goldberg, C
    Loew, J
    Venugopal, P
    BLOOD, 2001, 98 (11) : 273B - 273B
  • [3] Combination of pentoxifylline (PTX), ciprofloxacin (Cipro), dexamethasone (PCD) with amifostine improves ineffective hematopoiesis in patients with myelodysplastic syndromes (MDS).
    Raza, A
    Andric, T
    Qawi, H
    Venugopal, P
    Gezer, S
    Gregory, SA
    Hines, C
    Mundle, S
    Ali, A
    Shetty, V
    Mativi, BY
    Dar, S
    Loew, J
    Robin, EL
    Kozloff, M
    Galvez, A
    Rifkin, SD
    Alston, D
    Hernandez, BM
    Shah, R
    BLOOD, 1997, 90 (10) : 367 - 367
  • [4] Patients with Myelodysplastic Syndromes benefit from therapy with Amifostine, Pentoxifylline, and Ciprofloxacin with Dexamethasone.
    Turken, O
    Orhan, B
    Ozturk, A
    Etiz, D
    Yaylaci, M
    Uskent, N
    BLOOD, 2001, 98 (11) : 276B - 276B
  • [5] Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
    Raza, A
    Qawi, H
    Lisak, L
    Andric, T
    Dar, S
    Andrews, C
    Venugopal, P
    Gezer, S
    Gregory, S
    Loew, J
    Robin, E
    Rifkin, S
    Hsu, WT
    Huang, RW
    BLOOD, 2000, 95 (05) : 1580 - 1587
  • [6] Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS).
    Raza, A
    Lisak, L
    Little, L
    Ekbal, M
    du Rant, M
    Ali, E
    Nascimben, F
    Tareen, M
    Venugopal, P
    BLOOD, 2000, 96 (11) : 146A - 146A
  • [7] Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia
    Erikci, Alev Akyol
    Ozturk, Ahmet
    Karagoz, Bulent
    Bilgi, Oguz
    Turken, Orhan
    Top, Cihan
    Kandemir, E. Gokhan
    HEMATOLOGY, 2008, 13 (05) : 289 - 292
  • [8] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
    List, AF
    Holmes, H
    Greenberg, PL
    Bennett, JM
    Oster, W
    BLOOD, 1999, 94 (10) : 305A - 305A
  • [9] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis.
    List, AF
    Holmes, H
    Vempaty, H
    Greenberg, PL
    Bennett, JM
    BLOOD, 1998, 92 (10) : 714A - 714A
  • [10] Effect of pentoxifylline and ciprofloxacin (Cipro) on the levels of tumor necrosis factor alpha (TNF-alpha) in myelodysplastic syndromes (MDS).
    Shetty, V
    Gregory, S
    Gezer, S
    Venugopal, P
    Hines, C
    Mundle, S
    Alvi, S
    Borok, R
    Robin, E
    Rifkin, S
    Klein, M
    Alston, D
    Hernandez, B
    Hsu, WT
    Raza, A
    BLOOD, 1995, 86 (10) : 3193 - 3193
12345